Checkpoint agonists – immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis

Curr Opin Immunol. 2025 Aug 18;96:102641. doi: 10.1016/j.coi.2025.102641. Online ahead of print. ABSTRACT Psoriasis and psoriatic arthritis are chronic autoimmune diseases characterized by dysregulated immune responses, particularly involving Th17 cells. Immune checkpoint molecules such as programmed death-1 (PD-1) and its ligands (PD-L1/PD-L2) are critical for maintaining immune tolerance. Disruptions in these pathways contribute to psoriatic … Read more

SARS-CoV-2 and chronic kidney disease: challenges and future directions

Curr Opin Immunol. 2025 Aug 18;96:102642. doi: 10.1016/j.coi.2025.102642. Online ahead of print. ABSTRACT Patients with chronic kidney disease (CKD), especially those with end-stage kidney disease on dialysis or kidney transplant recipients (KTRs), are highly susceptible to infections, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic disproportionately affected this vulnerable population, … Read more

Can we cure lupus?

Curr Opin Immunol. 2025 Aug 14;96:102640. doi: 10.1016/j.coi.2025.102640. Online ahead of print. ABSTRACT A general understanding of the mechanisms leading to the development of systemic lupus has emerged over recent years, yet treatment of the illness remains largely empiric and unsatisfactory. Targeted therapy with monoclonal antibodies directed against B cells and against cytokines has met … Read more

B cell-targeted therapies in autoimmune skin disease: current advances and challenges

Curr Opin Immunol. 2025 Aug 14;96:102643. doi: 10.1016/j.coi.2025.102643. Online ahead of print. ABSTRACT Autoimmune skin diseases (AISDs) constitute a group of skin disorders driven by B cell-mediated autoimmunity or dysregulation of other immune cell populations. AISD can be further divided into systemic autoimmune disease with skin involvement, such as systemic lupus erythematosus (SLE), and skin-specific … Read more

Implication of epigenetic factors in development and recurrence of psoriasis

Curr Opin Immunol. 2025 Aug 14;96:102636. doi: 10.1016/j.coi.2025.102636. Online ahead of print. ABSTRACT Psoriasis is a chronic autoimmune skin disease characterized by abnormal proliferation and differentiation of keratinocytes, with a complex pathogenesis often linked to environmental and genetic factors. Although many treatments are available, the disease still exhibits a high recurrence rate. Epigenetic regulation appears … Read more

Can juvenile idiopathic arthritis be cured?

Curr Opin Immunol. 2025 Aug 11;96:102632. doi: 10.1016/j.coi.2025.102632. Online ahead of print. ABSTRACT Juvenile idiopathic arthritis (JIA) is the most common rheumatological disorder affecting children. It is characterized by chronic synovial inflammation that may lead to permanent joint damage and disability. JIA is an umbrella term for a heterogenous group of subtypes based on specific … Read more

Can sarcoidosis be cured?

Curr Opin Immunol. 2025 Aug 9;96:102637. doi: 10.1016/j.coi.2025.102637. Online ahead of print. ABSTRACT Sarcoidosis is a systemic granulomatous disease of unknown cause that affects the lungs almost invariably. The clinical course and outcomes of pulmonary sarcoidosis are highly variable, ranging from mild and self-limiting to organ-threatening or life-threatening disease. Often, sarcoidosis remits permanently (spontaneously or … Read more

Eliciting or silencing complement activation: strategies for optimizing monoclonal antibodies functions

Curr Opin Immunol. 2025 Aug 7;96:102638. doi: 10.1016/j.coi.2025.102638. Online ahead of print. ABSTRACT Tuning complement activity is essential to maximize therapeutic efficacy while minimizing off-target effects in monoclonal antibody (mAb) design. Complement-enhancing strategies are primarily applied to mAbs targeting pathogens, infected cells, tumors, or immunosuppressive cells within the tumor microenvironment. In contrast, complement-silencing strategies are … Read more

Intracellular complement in monocytes and macrophages: emerging roles

Curr Opin Immunol. 2025 Aug 6;96:102629. doi: 10.1016/j.coi.2025.102629. Online ahead of print. ABSTRACT Macrophages and the complement system are fundamental components of innate immunity, emerging early in evolutionary history. The well-established functions of complement in relation to macrophages contribute to both innate and adaptive immunity and are mediated by extracellular components acting systemically or locally … Read more

Complement in antiphospholipid syndrome, time to target?

Curr Opin Immunol. 2025 Aug 6;96:102628. doi: 10.1016/j.coi.2025.102628. Online ahead of print. ABSTRACT Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia. Complement system, which shares common actors with the coagulation cascade, is nowadays well established to be implicated in APS pathophysiology by different mechanisms. In APS, complement activation assessment is not included in the routine … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri 301 Moved Permanently

301 Moved Permanently


nginx/1.24.0 (Ubuntu)